Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia ( AML) Patients ( pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance])
- Citation:
- Blood vol 126 (23) 6
- Meeting Instance:
- ASH 2015
- Year:
- 2015
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2567
- Pharmas:
- Novartis
- Grants:
- U10CA180821, U10CA180882, U10CA31946
- Corr. Author:
- Authors:
- Richard M. Stone Sumithra Mandrekar Ben L Sanford Susan Geyer Clara D. Bloomfield Konstanze Dohner Christian Thiede Guido Marcucci Francesco Lo-Coco Rebecca B. Klisovic Andrew Wei Jorge Sierra Miguel A. Sanz Joseph M. Brandwein Theo de Witte Dietger Niederwieser Frederick R. Appelbaum Bruno C. Medeiros Martin S Tallman Jurgen Krauter Richard F. Schlenk Arnold Ganser Hubert Serve Gerhard Ehninger Sergio Amadori Richard A. Larson Hartmut Dohner
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007
- Study
- CALGB-10603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: